Adaptive Biotechnologies Corp (ADPT NASDAQ) stock market data APIs
$14.8072
1.45(9.8%)
as of December 5, 2025
Try our APIs with
free plan!
Adaptive Biotechnologies Corp Financial Data Overview
Price chart is built with
Anychart
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Prev. Close
14.8072
Open
16.253
High
16.3689
Low
14.5621
52 wk Range
5.805-20.76
Market Cap
2 252 M
Shares Outstanding
153 M
Revenue
253 M
EPS
0.06
Beta
2.204
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Adaptive Biotechnologies Corp (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adaptive Biotechnologies Corp data using free add-ons & libraries
Get Adaptive Biotechnologies Corp Fundamental Data
Adaptive Biotechnologies Corp Fundamental data includes:
- Net Revenue: 253 M
- EBITDA: -60 101 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adaptive Biotechnologies Corp News
New
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sy...
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback
Adaptive Biotechnologies (ADPT) has quietly turned into a powerful comeback story, with the stock up almost 180% over the past year, even as the business still runs at a loss. See our latest analysis...
Future in Tech Appoints Ed Moyle as Chief Information Security Officer
Ed Moyle, Chief Information Security Officer Veteran security strategist and AI security expert joins FiT to advance enterprise cybersecurity, strengthen product-level protection, and elevate industr...
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Adaptive Biotechnologies Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development SEATTL...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
